ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

10vHPV

Its studies are mostly in Papillomavirus Infections, led by Serum Institute of India Pvt.

Furthest: phase 2, since Sep 26, 20261 company-led study, 1 open or runningNext primary completion: Feb 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Serum Institute of India Pvt.11 open or runningphase 2since Sep 26, 2026Sep 26, 2026Feb 2028phase 2 · NCT07888686

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 26, 2026First study: phase 2 study in Papillomavirus InfectionsFirst studyNCT07888686 · 72 planned · Australia

Ahead

  1. Feb 2028Primary completion: phase 2 study in Papillomavirus InfectionsNCT07888686

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07888686Papillomavirus Infections · Australia2Not yet recruitingFeb 202872

How it is read

Names in the registry

  • “10vHPV”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.